|
Showing 1 - 2 of
2 matches in All Departments
It was estimated that in 2008, 1,437,180 patients would receive a
new cancer diagnosisand 565,650individualswould die of cancer
(Jemal et al. 2008).Since the vast majority of patients dying of
cancer will have had anticancer therapy, both c- ventional
chemotherapy and novel targeted therapy, it can be concluded that
these patients are dying with drug resistant cancer. The term
multidrug resistance is also apt - in that these patients die after
having undergone multiple rounds of different and structurally
unrelated cancer therapies. However, for some, the concept of m-
tidrug resistance is a worn out idea, stemming from disappointment
with the drug
resistancereversalstrategiesthatwerecarriedoutinthe1990susingpumpinhibitors
to block drug resistance mediated by P-glycoprotein, product of the
MDR-1 gene. However, if one takes the larger de?nition - multidrug
resistance as simultaneous resistance to multiple structurally
unrelated anticancer therapies - its existence c- not be denied.
The purpose of this book is to explore new concepts related to drug
resistance in cancer, including resistance to the new molecularly
targeted agents. Perhaps new terminology is needed for resistance
that occurs following therapy with the targeted agents: Novel
Targeted Agent Resistance (NTR). Alternatively, we can return to
the original de?nition of multidrug resistance as simply the res-
tance to multipleagents that occurs in the course of normalcancer
progression.This resistance is likely to be mediated by many
factors.
It was estimated that in 2008, 1,437,180 patients would receive a
new cancer diagnosisand 565,650individualswould die of cancer
(Jemal et al. 2008).Since the vast majority of patients dying of
cancer will have had anticancer therapy, both c- ventional
chemotherapy and novel targeted therapy, it can be concluded that
these patients are dying with drug resistant cancer. The term
multidrug resistance is also apt - in that these patients die after
having undergone multiple rounds of different and structurally
unrelated cancer therapies. However, for some, the concept of m-
tidrug resistance is a worn out idea, stemming from disappointment
with the drug
resistancereversalstrategiesthatwerecarriedoutinthe1990susingpumpinhibitors
to block drug resistance mediated by P-glycoprotein, product of the
MDR-1 gene. However, if one takes the larger de?nition - multidrug
resistance as simultaneous resistance to multiple structurally
unrelated anticancer therapies - its existence c- not be denied.
The purpose of this book is to explore new concepts related to drug
resistance in cancer, including resistance to the new molecularly
targeted agents. Perhaps new terminology is needed for resistance
that occurs following therapy with the targeted agents: Novel
Targeted Agent Resistance (NTR). Alternatively, we can return to
the original de?nition of multidrug resistance as simply the res-
tance to multipleagents that occurs in the course of normalcancer
progression.This resistance is likely to be mediated by many
factors.
|
|